Introduction 1
Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignant 2 tumors. Multi-disciplinary treatments including radio-and chemotherapy still poorly 3 control the progression of this disease, and its mean survival is less than one year after 4 initial diagnosis (1). Therefore, there is a critical need to develop a novel approach to 5 treat patients with ATC. 6 7 Docetaxel is an anticancer microtubule-stabilizing agent which induces apoptosis by 8 suppressing the microtubule dynamics of mitotic apparatus. Docetaxel also arrests cells 9 in G2/M phase, leading to increase of sensitivity of cancer cells to radio-and 10 chemotherapy (2) (3) (4) . Although the effect of the drug alone was only modest against 11 ATC in a clinical trial (5), combined therapy with radiation and/or another type of drug 12 may be effective (6) (7) (8) . 13 14 Imatinib (also known as STI571, Glivec, or Gleevec) is a selective tyrosine kinase 15 inhibitor and was originally developed to inhibit BCR/ABL fusion oncoprotein 16 expressed in chronic myelogenous leukemia (CML). It also cross-reacts with other 17 tyrosine kinases such as c-ABL, c-KIT, and platelet-derived growth factor receptors 18 (PDGFRs) and has been used for the treatment of gastrointestinal stromal tumor, small 19 cell lung cancer, ovarian cancer, and colorectal carcinoma (9) (10) (11) (12) (13) . In preclinical cancer 20 models, we have already reported the partial effectiveness of imatinib on ATC cells 21 (14) . We have also demonstrated that imatinib combined with ionizing radiation 22 enhanced senescence-like growth arrest (SLGA) (15). Very recently, a clinical trial 23 using imatinib as a single agent for the treatment of ATC has shown weak responses: no 24 complete response, 25% partial response and 50% stable disease at 8 weeks but the rate 25 of 6-month survival was only 45% (16). 26
27
Several reports have demonstrated that imatinib enhanced the sensitivity of various 28 cancer cells to anti-cancer drugs (9, 17) . A few studies have investigated the anti-cancer 29 efficacy of imatinib/docetaxel combination in preclinical models. It was shown that the 30 combination of imatinib and docetaxel was significantly more effective than either imatinib, as an inhibitor of PDGF-Rβ, decreased microvessel density and interstitial 1 fluid pressure, and thereby improved subsequent delivery of docetaxel (18). Another 2 report showed that in human CML cells, the imatinib/docetaxel combination induced 3 apoptosis through decreasing mitochondrial membrane potential and increasing 4 caspase-3 enzyme activity (19). Kinsella et al. reported that imatinib combined with 5 docetaxel strongly inhibited both proliferation and invasion, and had a pro-apoptotic 6 effect in glioma cells (20) . So far, there has been no report studying the therapeutic 7 efficacy of the imatinib/docetaxel combination in ATC. 8 9
In this study, we demonstrate that imatinib enhanced anti-tumor activity of docetaxel in 10 ATC cells. Docetaxel seemed to induce both pro-apoptotic and anti-apoptotic signaling 11 pathways, and imatinib blocked the anti-apoptotic signal through inhibition of 12 docetaxel-induced NF-κB activation. 13 14 15
Materials and Methods 16
Reagents 17 Imatinib (Novartis, Basel, Switzerland) was dissolved in dimethylsulfoxide (DMSO) at 18 stock concentration of 7 mM for in vitro experiments, and for in vivo experiments, 19 imatinib tablets were dissolved in distilled water, and insoluble material was removed 20 by repeated centrifugation at 2,500 g as described previously (21) . Docetaxel (Wako 21 Chemicals, Osaka, Japan) was dissolved in DMSO at a stock concentration of 1 mM. 22
The antibodies to p65, survivin, and β-actin were obtained from Santa Cruz 23 Biotechnology (Santa Cruz, CA, USA); the antibodies to X-linked inhibitor of apoptosis 24 (XIAP), cleaved caspase-3, poly (ADP-ribose) polymerase (PARP), IκBα, and 25 anti-rabbit and anti-mouse HRP-conjugated antibodies were from Cell Signaling 26 Technology (Beverly, MA, USA). The SA-β-gal staining was performed as described elsewhere (23). Briefly, after 25 experimental treatment, cells on plates were fixed with 2% (v/v) formaldehyde/0.2% 26 (v/v) glutaraldehyde, washed with PBS and assayed for SA-β-gal activity using X-gal 27
(5-bromo-4-chloro-3-indolyl β-D-galactosidase) at pH 6.0. SA-β-gal + cells were 28 detected by bright-field microscopy. 29 appropriate primary antibody, the antigen-antibody complexes were visualized using 3 HRP-conjugated secondary antibody and a chemiluminescence system (Nacalai Tesque, 4 Kyoto, Japan) Detection was performed using a LAS3000 imaging system (FUJIFILM, 5 Tokyo, Japan). 6 7 DNA-binding assay 8
The multiwell colorimetric assay for active NF-κB was performed as described 9 previously (24). Briefly, equal amount of nuclear extracts were incubated in 96-well 10 plate coated with immobilized oligonucleotide containing a NF-κB consensus binding 11 site. NF-κB binding to the target oligonucleotide was detected with primary antibody 12 specific for p65 subunit and HRP-conjugated secondary antibody. For quantification of 13 activity, ODs were measured at 450 nm using a microplate reader 2030 ARVO X 14 (PerkinElmer Inc., Waltham, MA, USA). 15
16
In vivo xenograft model 17
All mice were maintained at Nagasaki University animal facility, and all animal 18 experiments described in this study were conducted in accordance with the principles 19 and procedures outlined in the Guide for the Care and Use of Laboratory Animals of 20 Nagasaki University. FRO cells (3×10 6 ) resuspended in RPMI 1640 were injected s.c. 21 into both flanks of 6-week-old male BALB/c nu/nu mice (CLEA Japan, Tokyo, Japan), 22 five animals per group. Then they were randomly assigned into four groups. The tumor 23 sizes were measured every three days with calipers, and tumor volumes were calculated 24 according to the formula: a 2 ×b×0.4, where a is the smallest tumor diameter and b is the 25 diameter perpendicular to a. Imatinib solution in sterile water/PBS (ratio 1:1) was 26 injected i.p. daily for 2 weeks at a dose of 50 mg/kg beginning from day 9 after tumor 27 implantation. Docetaxel, diluted in PBS/DMSO (ratio 1:1), was injected i.p. at a dose of 28 as indicators of general health. 1 2
Statistical Analysis 3
All data were expressed as the mean ± SD. Differences between groups were examined 4 for statistical significance with ANOVA followed by Tukey's post test. A p value not 5 exceeding 0.05 was considered statistically significant. 6 7 8
Results 9
Inhibition of cell growth by docetaxel and/or imatinib 10
To investigate the effect of docetaxel and/or imatinib, cell growth assay was done. Our 11 previous experiments (7, 14); (unpublished data) demonstrated that moderate cell 12 growth inhibition by imatinib and docetaxel was observed at concentrations of 7 µM 13 and 1~2 nM in FRO cells, respectively. Thus, we conducted the experiments using 7 14 µM of imatinib and 1 nM of docetaxel. As shown in Fig. 1 , both docetaxel and imatinib 15 had moderate inhibitory effect on the growth of FRO cells, and combined treatment 16 significantly reduced the cell number compared to single treatment (Fig. 1) . We also 17 used another ATC cell line, KTC-2 cells, in which the growth inhibition by imatinib 18 was less effective compared to FRO cells, and the potency of docetaxel was more 19 pronounced. The combined treatment similarly inhibited the cell growth, almost 20 completely (Fig. 1) . The rates of growth reduction at 4 days in docetaxel, imatinib, and 21 combined treatment were 47.3%, 68.5%, and 96.0% in FRO cells and 76.1%, 29.6%, 22 and 99.5% in KTC-2 cells, respectively (Fig. 1) . 23 24
Apoptotic changes in cells treated with the drugs 25
Although the degree of cell detachment was more notable in the combined treatment 26 than in single treatment group, we first explored the possibility of involvement of that imatinib plus radiation therapy enhanced SLGA in ATC cells (15). Neither single 1 treatment nor combined treatment did induce SA-β-gal activity in both FRO and KTC-2 2 cell lines, suggesting that the growth inhibitory effect was not due to SLGA (data not 3 shown). Next, we examined whether the effect was associated with apoptosis. Cells 4 were treated with the drugs for 16 hours and then double stained with FITC-conjugated 5 annexin V and PI to look at early apoptotic response (right lower quadrant in each dot 6 plot in Fig. 2 ) and subsequent cell death (right upper quadrant). Imatinib barely caused 7 apoptosis, and docetaxel moderately induced it. On the other hand, the combined 8 treatment further increased apoptosis (Fig. 2) . 9 10
Effects of docetaxel and imatinib on pro-apoptotic and anti-apoptotic factors 11
We next examined the status of several key proteins involved in apoptosis by Western 12 blotting. After ATC cells were treated with docetaxel, the cleavages of caspase-3 ( 19 13 kDa and 17 kDa) and PARP (89 kDa) levels were induced (Fig. 3) . The cleaved PARP 14 and caspase-3 were further increased by the combined treatment, suggesting stronger 15 apoptotic change (Fig. 3) . XIAP and survivin belong to the human inhibitors of 16 apoptosis (IAP) family, and their overexpression in cancer cells suggests an important 17 role for these proteins in cancer progression. We tested whether docetaxel and/or 18 imatinib modulate the expression of these anti-apoptotic gene products by Western 19 blotting. As shown in Fig. 3 , although ATC cells themselves expressed high levels of 20 XIAP and survivin, docetaxel further increased the levels (Fig. 3) . Single treatment of 21 imatinib did not change their background levels; however, the increased 22 docetaxel-induced XIAP and survivin expression was suppressed in the combination 23 treatment (Fig. 3) . 24
Since we already reported that the expression of those anti-apoptotic factors was 1 regulated through NF-κB signaling pathway in ATC cells (7), we next performed 2 DNA-binding assay using nuclear extracts to assess NF-κB activity. In both FRO and 3 KTC-2 cell lines, the binding activity of nuclear p65 was increased by docetaxel 4 treatment. Although imatinib alone had no effect on NF-κB background levels, in the 5 combined treatment, imatinib significantly suppressed the docetaxel-induced NF-κB 6 activation (Fig. 4A) . A similar trend was observed in the amount of nuclear p65 (Fig.  7 4B). We also checked IκBα expression. As shown in Fig. 4B , the combined treatment 8 reduced IκBα protein level, consistent with our previous studies (7, 25) . NF-κB is 9 known to bind the IκBα promoter and activate its synthesis, and therefore the inhibition 10 of NF-κB probably suppressed de novo synthesis of IκBα. Presumably, for the same 11 reason, IκBα expression after docetaxel treatment was not changed (Fig. 4B) . 12 13
In vivo effects of the combined treatment with docetaxel and imatinib 14
To explore the effects of the combined treatment in vivo, we used an animal xenograft 15 model inoculated with FRO cells, and the treatments were done as described in imatinib-treated group was smaller than that of control, but there was no statistical 18 difference. Although the docetaxel treatment alone was able to delay tumor growth 19 moderately, the effect of the combined treatment with docetaxel and imatinib was far 20 greater. The body weight and physical activity of mice exposed to drugs were not 21 significantly affected. 22 23 24 Discussion 25 12 are induced through NF-κB activation (7, 26, 27) . NF-κB is a transcription factor that 1 regulates genes involved in cellular proliferation and survival (28). In most cases, 2 NF-κB suppresses apoptosis by up-regulation of anti-apoptotic proteins, including 3 inhibitor of apoptosis (IAP), such as c-IAP, XIAP, and survivin (29, 30) . In 4 addition, basal NF-κB activity is often increased in various types of human cancers, 5 which causes chemotherapy resistance (31). Under certain conditions, cytotoxic drugs 6 such as taxanes induce NF-κB activation in different types of malignant cells (26, 7 32-36) . The present data also showed that docetaxel induced NF-κB activation and then 8 up-regulated anti-apoptotic factors in two ATC cell lines, FRO and KTC-2. 9
10
In our experiments, imatinib seemed to enhance apoptosis presumably through the 11 inhibition of docetaxel-induced NF-κB activation. There are several reports proposing 12 the mechanism by which imatinib inhibits the docetaxel-induced NF-κB activation. The 13 PI3K/AKT pathway has been associated with cancer cell resistance to chemotherapeutic 14 drugs including paclitaxel (34, 37) . Possible mechanisms of such resistance may be due 15 to the activation of the NF-κB pathway via PI3K/AKT activation (38) . Qian et al. 16 compared the gene expression profiles in individual human prostate cancer specimens 17 before and after chemotherapy and showed that docetaxel treatment increased CCL2 18 expression (39). They also showed that up-regulation of CCL2 contributed to 19 chemotherapy resistance through stimulating MAP kinase and PI3K/AKT signaling 20 pathways. Several other reports have demonstrated that imatinib inhibited the 21 PI3K/AKT pathway, resulting in the inhibition of NF-κB activation in cancer cells. 22 imatinib inhibited IR-induced RelB nuclear translocation by decreasing the 26 phosphorylation levels of PI3K (Tyr458) and AKT (Ser473) in androgen-independent prostate cancer cells (41). They showed that imatinib inhibited PI3K tyrosine 1 phosphorylation, leading to the down-regulation of the AKT/IKKα-activated NF-κB 2 pathway. We examined whether docetaxel and/or imatinib modulate the 3 phosphorylation level of AKT. However, we could detect neither the activation of AKT 4 by docetaxel treatment nor the inhibition of AKT by imatinib (data not shown). Further 5 experiments are necessary to clarify the exact mechanism by which imatinib inhibits the 6 docetaxel-induced NF-κB activation in ATC cells. 7 8 Data obtained in our experiments showed that combination of docetaxel and imatinib 9 effectively killed ATC cells, both in vitro and in vivo. Based on our and other's findings, 10
we propose a mechanistic scheme in Fig. 6 . As previously shown, docetaxel activates 11 both pro-apoptotic and anti-apoptotic signals. In pro-apoptotic pathway, docetaxel binds 12 to microtubules, impairs mitosis, and induces apoptosis. In anti-apoptotic pathway, 13 docetaxel also induces NF-κB activation and in turn increases the expression of 14 anti-apoptotic molecules. Imatinib inhibits the docetaxel-induced NF-κB activation (but 15 does not reduce the basal NF-κB level, even though it is high). By this mechanism, 16 imatinib presumably modulates the balance between pro-and anti-apoptotic signals and 17 enhances docetaxel-induced apoptosis. 18
19
In conclusion, our present study demonstrates that imatinib enhanced anti-tumor activity 20 of docetaxel in ATC cells, suggesting that this combination may be a promising 21 approach for the treatment of ATCs. Since docetaxel and imatinib have already been 22 approved and currently being used for other type of cancers, this combination strategy 23 can be rapidly applied to clinical trial. 
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